Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma.

Autor:	Won WJ; Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Deshane JS; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Leavenworth JW; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA., Oliva CR; Free Radical and Radiation Biology Program, The University of Iowa, Iowa City, IA 52242, USA., Griguer CE; Free Radical and Radiation Biology Program, The University of Iowa, Iowa City, IA 52242, USA.
Jazyk:	angličtina
Zdroj:	Cell stress [Cell Stress] 2019 Jan 23; Vol. 3 (2), pp. 47-65. Date of Electronic Publication: 2019 Jan 23.
DOI:	10.15698/cst2019.02.176
Abstrakt:	Glioblastoma, also known as glioblastoma multi-forme, is the most common and deadliest form of high-grade malignant brain tumors with limited available treatments. Within the glioblastoma tumor microenvironment (TME), tumor cells, stromal cells, and infiltrating immune cells continuously interact and exchange signals through various secreted factors including cytokines, chemokines, growth factors, and metabolites. Simultaneously, they dynamically reprogram their metabolism according to environmental energy demands such as hypoxia and neo-vascularization. Such metabolic re-programming can determine fates and functions of tumor cells as well as immune cells. Ultimately, glioma cells in the TME transform immune cells to suppress anti-tumor immune cells such as T, natural killer (NK) cells, and dendritic cells (DC), and evade immune surveillance, and even to promote angiogenesis and tumor metastasis. Glioma-associated microglia/macrophages (GAMM) and myeloid-derived suppressor cells (MDSC) are most abundantly recruited and expanded myeloid lineage cells in glioblastoma TME and mainly lead to immunosuppression. In this review, of myeloid cells we will focus on MDSC as an important driver to induce immunosuppression in glioblastoma. Here, we review current literature on immunosuppressive functions and metabolic reprogramming of MDSCs in glioblastoma and discuss their metabolic pathways as potential therapeutic targets to improve current incurable glioblastoma treatment. Competing Interests: Conflict of interest: The authors declare no conflict of financial interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu